Antibody Response to Sars-CoV-2 in Adults After 18 Months of Second Dose Vaccination of Astra Zeneca

Open Access

Issue		BIO Web Conf. Volume 101, 2024 The 5^th International Conference on Life Sciences and Biotechnology (ICOLIB 2023)


Article Number		04001
Number of page(s)		9
Section		Health & Medicine
DOI		https://doi.org/10.1051/bioconf/202410104001
Published online		09 April 2024

Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K.-S. Leung, E.-H. Lau, J.-Y. Wong, X. Xing, Early transmission dynamics in wuhan, china, of novel coronavirus- infected pneumonia. New England journal of medicine. 382, 1199 (2020). http://doi.org/10.1056/NEJMoa2001316 [CrossRef] [PubMed] [Google Scholar]
WHO, Coronavirus disease (COVID-19) pandemic. https://www.who.int/europe/emergencies/situations/covid-19 [Google Scholar]
WHO, Coronavirus Disease 2019 (COVID-19) Situation Report - 1. (2020). https://www.who.int/docs/default-source/searo/indonesia/covid19/who-indonesia-situation-report-1.pdf?sfvrsn=6be5b3590 [Google Scholar]
WHO, COVID-19 epidemiological update. (2024). https://www.who.int/publications/m/item/covid-19-epidemiological-update-16-february-2024 [Google Scholar]
WHO, WHO updates guidelines on treatments for COVID-19. (2023). https://www.who.int/news/item/10-11-2023-who-updates-guidelines-on-treatments-for-covid-19 [Google Scholar]
A. Fotouh, Sawsan, A.-N. Mahmoud, E.-M. Elnahas, M.-Z. Habib, S.-M. Abdelraouf, What are the current anti - COVID - 19 drugs? From traditional to smart molecular mechanisms. Virology journal. 20, 1 (2023). http://doi.org/10.1186/s12985-023-02210-z [CrossRef] [Google Scholar]
H. Li, Y. Zhou, M. Zhang, H. Wang, Q. Zhao, Updated approaches against SARS-CoV- 2, Antimicrob Agents Chemother. 64, 1 (2020). https://doi.org/10.1128/AAC.00483-20 [Google Scholar]
COVID19 vaccine tracker, 13 Vaccines Approved for Use in Indonesia. https://covid19.trackvaccines.org/country/indonesia/ [Google Scholar]
M.-T. Mascellino, A. Oliva, Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy, and safety. Infection and drug resistance. 14, 3459 (2021). https://doi.org/10.2147/IDR.S315727 [CrossRef] [Google Scholar]
A.-I. Francis, S. Ghany, T. Gilkes, S. Umakanthan, Review of COVID- - 19 vaccine subtypes, efficacy and geographical distributions. Postgraduate medical journal. 98, 389 (2022). http://doi.org/0.1136/postgradmedj-2021-140654 [CrossRef] [PubMed] [Google Scholar]
E.-G. Levin, Y. Lustig, C. Cohen, R. Fluss, V. Indenbaum, S. Amit, R. Doolman, K. Asraf, E. Mendelson, A. Ziv, C. Rubin, Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. New england journal of medicine. 84, 1 (2021). http://doi.org/10.1056/NEJMoa2114583 [Google Scholar]
J. Favresse, J. Bayart, F. Mullier, J. Dogn, J. Doux, Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2), Clinical microbiology and infection. 27, 7 (2021). http://doi.org/10.1016Zj.cmi.2021.05.004 [Google Scholar]
Y. Cao, X. Hao, X. Wang, Q. Wu, R. Song, D. Zhao, W. Song, Y. Wang, A. Yisimayi, W. Wang, W. Zhang, Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine, Cell research. 32, 107 (2022). http://doi.org/10.1038/s41422-021-00596-5 [CrossRef] [PubMed] [Google Scholar]
A. Kitro, W. Sirikul, W. Thongkum, S. Soponpong, Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers, Vaccine. 40, 2915 (2022). http://doi.org/0.1016/j.vaccine.2022.04.020 [CrossRef] [Google Scholar]
WHO, Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID- 19 vaccine AZD1222 Vaxzevria TM. (2022). https://www.who.intZpublications/i/itemZWHO-2019-nCoV-vaccines-SAGErecommendation-AZD1222-2021.1 [Google Scholar]
C. Fenioux, L. Teixeira, S. Fourati, G. Melica, J.-D. Lelievre, S. Gallien, G. Zalcman, J.-M. Pawlotsky, C. Tournigand, SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents charlotte, JAMA Oncology. 8, 612 (2022). http://doi.org/0.1001/jamaoncol.2021.7777 [CrossRef] [PubMed] [Google Scholar]
S. Havervall, U. Marking, N. Greilert-Norin, M. Gordon, H. Ng, W. Christ, M. Phillipson, P. Nilsson, S. Hober, K. Blom, J. Klingström, Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time, Clinical & translational immunology. 11, 1 (2022). http://doi.org/10.1002/cti2.1388 [CrossRef] [Google Scholar]
H. Kusunoki, K. Ekawa, M. Ekawa, N. Kato, K. Yamasaki, M. Motone, H. Shimizu, Trends in antibody titers after SARS-CoV-2 vaccination — insights from self-paid tests at a general internal internal medicine clinic, Medicines. 10, 27 (2023). https://doi.org/10.3390/medicines10040027 [CrossRef] [Google Scholar]
Pemerintah putuskan vaksinasi booster mulai 12 Januari mendatang. https://www.kominfo.go.idZcontent/detailZ39173/pemerintah-putuskan-vaksinasi-booster-mulai-12-januari-mendatang/0/berita [Google Scholar]
BPOM issues emergency use authorization for five booster vaccines. https://setkab.go.idZenZbpom-issues-emergencv-use-authorization-for-five-booster-vaccines/ [Google Scholar]
CDC, Similarities and differences between Flu and COVID-19. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm [Google Scholar]
Abufares, H. Imad, L.-O. Alsoud, M.-A.-Y. Alqudah, M. Shara, N.-C. Soares, K.-H. Alzoubi, W. El-Huneidi, Y. Bustanji, S.-S.-M. Soliman, M.-H. Semreen, COVID-19 vaccines, effectiveness, and immune responses, International journal of molecular sciences. 24, 1 (2022). https://doi.org/10.3390/ijms232315415 [CrossRef] [Google Scholar]
Y. K. Ko, H. Murayama, L. Yamasaki, R. Kinoshita, M. Suzuki, H. Nishiura, Agedependent effects of COVID-19 vaccine and of healthcare burden on COVID-19 Deaths, Tokyo, Japan, Emerging Infectious Diseases. 28, 1777 (2022). http://doi.org/10.3201/eid2809.220377 [CrossRef] [PubMed] [Google Scholar]
Fernandes, M. D. C. Rodrigues, G. S. Vasconcelos, A. C. L. D. Melo, T. C. Matsui, L. F. Caetano, F. M. D. C. Araújo, M. H. G. Fonseca, Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases diseases in antibody response after COVID-19 vaccination: A review, Molecular immunology. 156, 148 (2023). https://doi.org/10.1016/j.molimm.2023.03.007 [CrossRef] [Google Scholar]
E. Goldstein, M. Lipsitch, M. Cevik, On the effect of age on the transmission of SARS- CoV-2 in households, schools and the community, The journal of infectious diseases. 223, 362 (2021). https://doi.org/10.1093/infdis/jiaa691 [Google Scholar]
M. Lipsitch, F. Krammer, G.-R. Yochay, Y. Lustig, R.-D. Balicer, SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact, Nature reviews immunology. 22, 57 (2022). https://doi.org/10.1038/s41577-021-00662-4 [CrossRef] [PubMed] [Google Scholar]
A. Ruggieri, S. Anticoli, A.-D. Ambrosio, L. Giordani, and M. Viora, The influence of sex and gender on immunity, infection and vaccination, 52, 198 (2016). [Google Scholar]
L. Capai, N. Ayhan, S. Masse, J. Canarelli, S. Priet, M.-H. Simeoni, R. Charrel, X.-D. Lamballerie, A. Falchi, Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020, Journal of Clinical Medicine, 9, 3569 (2020). https://doi.org/10.3390/jcm9113569 [Google Scholar]
A. Sanyaolu, C. Okorie, A. Marinkovic, R. Patidar, K. Younis, P. Desai, Z. Hosein, I. Padda, J. Mangat, M. Altaf, Comorbidity and its Impact on Patients with COVID-19, SN comprehensive clinical medicine, 2, 1069 (2020). https://doi.org/10.1007/s42399-020-00363-4 [CrossRef] [PubMed] [Google Scholar]
S. Lukas, D.-L. Ramatillah, Y. Aldi, F.-S. Wahyuni, K. Khan, Evaluation of increased antibody titer COVID-19 after AstraZeneca vaccination based on the age at UTA’45 Jakarta Vaccine Center, Asian journal of pharmaceutical research and health care, 15, 83 (2023). http://doi.org/10.4103/ajprhc.ajprhc423 [CrossRef] [Google Scholar]
C.-T. Chan, M. Lieu, B.-H. Toh, T.-S. Kyaw, A. Bobik, C.-G. Sobey, G.-R. Drummond, Antibodies in the pathogenesis of hypertension, 2014, 1 (2014). http://dx.doi.org/10.1155/2014/504045 [Google Scholar]
L. Barni, E.-C. Vega, M. Olivieri, A.-G. Mercant, S. Guiducci, F. Picariello, M.-G. Sánchez, Does physical exercise enhance the immune response after vaccination? A systematic review for clinical indications of COVID-19 vaccine, International journal of environmental research and public healt, 20, 5183 (2023). https://doi.org/10.3390/ijerph20065183 [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.